A new gel that helps stop bleeding for both emergency care and surgical procedures in animal medicine is being sought for FDA approval for a human version.
Share:
More In Science
Cannabis Europa Conference Underscores Emerging Opportunities in European Cannabis
The sold out event marked progress for the industry, and hammered home opportunities ー and challenges ー on the rise in one of the next frontiers for cannabis legalization: the European Union.
Vaping Patients Surge Past 2,000 as CDC Narrows in on a Chemical Culprit
New research from the agency, released on Friday, examined lung fluid samples from victims of e-cigarette, or vaping, product use associated lung injury (EVALI) and found vitamin E acetate in 100 percent of samples from 29 patients across 10 states.
OPEC: Global Energy Demand to Climb 25 Percent by 2040
As the world's population swells to 9.2 billion people and developing nations meet demands for electrification, global demand for energy will soar by 25 percent by 2040, according to the 2019 World Oil Outlook published by OPEC.
Need 2 Know: Nats Win, Twitter Bans Political Ads
These are the headlines you Need 2 Know for Thursday, October 31, 2019.
Need 2 Know: Winds Fanning Flames, Cities Underwater
These are the headlines you Need 2 Know for Wednesday, October 30, 2019.
Need 2 Know: ISIS Leader Dead, Brexit Extended Again
These are the headlines you Need 2 Know for Monday, October 28, 2019.
Minnesota Timberwolves Eating Better Thanks to Data This NBA Season
A partnership with food distributor KZ Provisioning, the Mayo Clinic, and celebrity chefs have helped the team figure out what exactly each individual player needs to hit max performance on the court.
New Earthquake Alert App Could Help Californians Brace for Tremors
UC Berkeley's Seismological lab is working to give people state-wide a heads-up next time a quake comes their way with the new MyShake app for iPhones and Androids.
Biogen Shares Soar After Announcing Alzheimer's Drug Breakthrough
The surprise announcement, which sent shares up nearly 40 percent in early trading hours, comes months after Biogen discontinued research on the drug.
